This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Pharma Solutions operates 10 research and development and/or production sites globally
The pilot plant is focused on scaling up beverage production and will support applications
Subscribe To Our Newsletter & Stay Updated
